PACIRA BIOSCIENCES, INC. Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer
PACIRA BIOSCIENCES, INC. (PCRX) reported Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer of $125.00 thousand for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-28.
Discontinued › Income Statement › Other Income
us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer · last filed 2022-02-28
- PACIRA BIOSCIENCES, INC. revenue from collaborative arrangement, excluding revenue from contract with customer for fiscal 2021 was $125.00K.
- PACIRA BIOSCIENCES, INC. revenue from collaborative arrangement, excluding revenue from contract with customer for fiscal 2020 was $0.00.
- PACIRA BIOSCIENCES, INC. revenue from collaborative arrangement, excluding revenue from contract with customer for fiscal 2019 was $0.00.
| Period end | Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer 12 month |
|---|---|
| 2021-12-31 | $125.00K 10-K · filed 2022-02-28 |
| 2020-12-31 | $0.00 10-K · filed 2022-02-28 |
| 2019-12-31 | $0.00 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |